

## Index

- A1C, S4, **S18–S19**  
 advantages of, S18  
 and cardiovascular disease outcomes, S88–S89  
 confirming diagnosis with, S19  
 correlation with BGM, S84  
 in diagnosis of adults, S18–S19  
 in diagnosis of children, S18–S19  
 differences in children, S84–S85  
 hemoglobinopathies and, S19  
 limitations, S84  
 other conditions affecting, S19  
 point-of-care assays, S4, S18  
 in prediabetes, S23  
 in pregnancy, S235  
 race/ethnicity and, S19, S84–S85  
 recommendations, S19  
 setting and modifying goals for, S89–S90
- acarbose, S121, S137  
 access to care, S10–S11  
 access, to insulin, S254–S255  
 ACCORD study, S54, S87–S88, S91, S146, S147, S148, S154, S178, S179, S197  
 ACE inhibitors, S6, S7, S51, S148, S149, S150, S158, S176, S178, S181, S182, S209, S216, S218, S222, S233, S239  
 acute kidney injury, S150, S178  
 ADA consensus report, S1–S2  
 ADA evidence-grading system, S2  
 ADA Professional Practice Committee, S1, **S3**  
 ADA statements, S1  
 ADAG study, S84–S85, S90, S91  
 Addison disease, S53  
 adolescents. *see* children and adolescents.  
 adrenal insufficiency, primary, S53  
 adult-onset diabetes. *see* Type 2 diabetes.  
 adults, prediabetes and diabetes screening in, S22, S25–S26  
 ADVANCE trial, S87–S88, S91, S146, S147  
 advocacy statements, S7, **S254–S255**  
 care of young children with diabetes in the childcare setting, S255  
 diabetes and driving, S255  
 diabetes and employment, S255  
 diabetes care in correctional institutions, S255  
 diabetes care in the school setting, S255  
 insulin access and affordability, S254–S255
- affordability, of insulin, S254–S255  
 African Americans, S11, S20, S21, S22, S25, S68, S91  
 A1C variability in, S19, S23, S84–S85  
 BMI cut point in, S26
- age  
 effect on A1C, S19–S20  
 risk factor for diabetes, S25  
 statin treatment and, S151
- agricultural workers, migrant, S12  
 AIM-HIGH trial, S154–S155  
 albiglutide, S165, S166, S167  
 albuminuria, S66, S70, S91, S133, S145, S147, S149, S150, S156, S167, **S176**, S177, S178, S179, S180, S181, S182, S215, S217, S218  
 alcohol intake, S67  
 alirocumab, S153
- alogliptin, S133, S137, S159, S167, S247  
 alpha-glucosidase inhibitors, S137  
 ambulatory glucose profile (AGP), S85, S86, S87  
 amputation, foot, S190, S191  
 analogs. *see* insulin analogs.  
 angiotensin receptor blockers (ARBs), S6, S149, S150, S158, S178, S180, S181, S182, S209, S210  
 anti-VEGF agents, S187–S188  
 antibiotics, S192  
 antiplatelet agents, S155–S157  
 antipsychotics, atypical, S26, S74  
 antiretroviral therapies, S26  
 anxiety disorders, S72  
 ARRIVE trial, S156  
 ASCEND trial, S66, S156, S157  
 Asian Americans, S22, S25–S26, S119, S120  
 aspart, S27, S126, S138, S201  
 aspirin therapy, S155, S156, S239  
 ASPREE trial, S156  
 atenolol, S190  
 atherosclerotic cardiovascular disease (ASCVD), **S144–S174**  
 atorvastatin, S152  
 atypical antipsychotics, S26, S74  
 autoimmune diseases, **S53, S215**  
 automated insulin delivery (AID) systems, S5, S98, S104–S105, S126, S213  
 autonomic neuropathy, S70  
 autonomic neuropathy, diabetic, S188
- balloons, implanted gastric, S119  
 bariatric surgery. *see* metabolic surgery.  
 basal insulin, S99, S126, S139  
 bedtime dosing, of antihypertensives, S150  
 behavior changes, S5, S10, **S60–S82**  
 diabetes self-management education and support, **S60–S62**  
 medical nutrition therapy, **S62–S67**  
 physical activity, **S67–S70**  
 in pregnancy, S236  
 psychosocial issues, **S70–S75**  
 smoking cessation, **S70**  
 for weight loss, S114–S115
- bempeidic acid, S153–S154  
 beta-cell replacement therapy, S130–S131  
 biguanides, S137  
 bladder dysfunction, S189  
 Blood Glucose Awareness Training, S5, S72, S92  
 blood glucose monitoring (BGM), S5, S83, S84, S85, S89, S90, S92, S129, S221  
 bedside, in hospitalized patients, **S246**  
 correlation with A1C, S84  
 devices for, **S98–S100**  
 in hypoglycemia, S90–S92  
 in intensive insulin regimens, S99  
 during pregnancy, S235
- blood pressure control. *see also* hypertension., **S145–S150**, S181  
 body mass index (BMI), S5, S18, S22, S25–S26, S114, S115, S116, S119, S120, S219, S221, S222, S237, S239  
 bone mineral density (BMD), S55  
 bromocriptine, S137
- calcium channel blockers, S149, S150  
 canagliflozin, S133, S137, S162, S164, S167, S180, S181, S616  
 cancer, risk in diabetes, S53  
 CANVAS study, S162, S163, S164, S180, S181  
 capsaicin, topical, S190  
 carbamazepine, S190  
 carbohydrate intake, S4, S5, S65–S66  
 cardiac autonomic neuropathy, diabetic, S188–S189  
 cardiac function testing, S223  
 cardiovascular disease, S6, **S144–S174**  
 A1C and outcomes of, S88–S89  
 antiplatelet agents, **S155–S157**  
 cardiac testing, S159  
 hypertension/blood pressure control, **S145–S150**  
 lifestyle and pharmacologic interventions, **S159–S169**  
 lipid management, **S151–S155**  
 prevention of, in prediabetes, **S42–S43**, S223  
 screening, S157–S159
- cardiovascular risk  
 in pediatric type 1 diabetes, S216  
 risk calculator, **S145**
- care delivery systems, S9–S11  
 access to care and quality improvement, S10–S11  
 behaviors and well-being, S10  
 care teams, S10  
 chronic care model, S9  
 medication cost considerations, S10  
 six core elements, S9  
 system-level improvement strategies, S9–S10
- care teams, S10  
 CARMELINA trial, S159, S167  
 CAROLINA trial, S159, S161  
 celiac disease, S53  
 in pediatric type 1 diabetes, S209, S215–S216  
 Charcot neuropathy, S69, S70, S190, S191  
 childcare, S212, S255  
 children and adolescents, S7, **S208–S231**  
 A1C in, S19–S20, S84–S85  
 asymptomatic, risk-based screening in, S23  
 cystic fibrosis-related diabetes in, **S27**  
 diabetes care in childcare settings, S212, S255  
 diabetes care in school setting, S98, S212, S254–S255  
 insulin pumps in, S104  
 maturity-onset diabetes of the young (MODY), S17, **S28–S29**  
 monogenic diabetes syndromes, S17, S28–S30  
 neonatal diabetes, S17, S28–S29  
 physical activity in, S68, S69  
 recommendations for screening and treatment, S209–S210  
 screening for prediabetes and type 2, S26  
 transition from pediatric to adult care, **S224**  
 type 1 diabetes in, **S211–S218**  
 type 2 diabetes in, **S218–S224**

- China Da Qing Diabetes Prevention Outcome Study, S42–S43
- CHIPS trial, S148
- cholesterol lowering, S151
- chronic care model, S9
- chronic kidney disease, diabetic, S6–S7, **S175–S184**
- acute kidney injury, S178
  - assessing albuminuria and GFR, S176–S177
  - diagnosis, S177
  - interventions for, S179–S182
  - referral to nephrologist, S182
  - risk of progression, S177
  - screening recommendations, S175
  - staging, S177–S178
  - surveillance, S178–S179
  - treatment recommendations, S175–S176
- classification, S4, **S17–S18**
- clonidine, S190
- clopidogrel, S155, S157
- closed-loop systems
- do-it-yourself, S105
  - hybrid, S126
- coaching, online, S105
- cognitive capacity/impairment, S5, S53–S54, S74–S75
- colesevelam, S137
- collaborative care, **S46–S48**
- collagen vascular diseases, S53
- community health workers, S4
- community screening, S26
- community support, S13
- comorbidities, assessment of, **S46–S59**
- autoimmune diseases, **S53**
  - cancer, **S53**
  - cognitive impairment/dementia, **S53–S54**
  - fractures, **S55**
  - hepatitis C infection, **S54–S55**
  - low testosterone in men, **S55–S56**
  - nonalcoholic fatty liver disease, **S54, S55, S56**
  - obstructive sleep apnea, **S56**
  - pancreatitis, **S55**
  - periodontal disease, **S56**
  - sensory impairment, **S55**
- COMPASS trial, S157
- CONCEPT study, S235–S236
- connected insulin pens, S5, S102–S103
- continuous glucose monitoring (CGM), S5, **S85–S87**
- ambulatory glucose profile in, S85, S86, S87
  - devices for, **S100–S102**
  - in hospitalized patients, S246
  - in hypoglycemia, S92
  - in pediatric type 1 diabetes, S214
  - in pregnancy, S235–S236
  - recommendations, S85, S100–S101
  - standardized metrics for, S85
- continuous subcutaneous insulin infusion (CSII), S98, S125–S126
- coronary artery disease, S69, S149, S150, S157, S158
- correctional institutions, diabetes care in, S255
- cost considerations, S4, S10, S135, S137, S254–S255
- COVID-19 vaccines, **S51–S52**
- CREDESCENCE study, S162, S163, S164, S167, S180, S181
- cystic fibrosis-related diabetes, S17, **S27**
- DAMOCLES study, S192
- DAPA-CKD study, S6, S164, S180
- DAPA-HF study, S6, S164
- dapagliflozin, S133, S137, S162, S164, S166, S167, S180, S181
- DASH diet, S148, S151
- DECLARE-TIMI 58 study, S164
- degludec, S126, S138, S139, S140, S201
- delay, of type 2 diabetes, S4–S5, **S39–S45**
- lifestyle behavior change, **S40–S42**
  - patient-centered care goals, **S43**
  - pharmacologic interventions, **S42**
  - prevention of vascular disease and mortality, **S42–S43**
- dementia, in diabetics, S53–S54
- hyperglycemia and, S54
  - hypoglycemia and, S54
  - nutrition and, S54
  - statins and, S54
- dental practices, screening in, S26
- depression, S72–S73
- detemir, S128, S138, S139, S201
- devices. *see* technology.
- Diabetes Control and Complications Trial (DCCT), S19, S87, S88, S89, S90, S91, S105, S125, S126, S214, S218
- Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC), S55, S88, S89, S91, S179
- diabetes distress, S71–S72
- diabetes medical management plan (DMMP), for students, S98
- Diabetes Prevention Impact Tool Kit, S41
- Diabetes Prevention Program (DPP), S23, **S40**
- delivery and dissemination of, S41–S42
- Diabetes Prevention Recognition Program (DPRP), S42
- diabetes self-management education and support (DSMES), S5, S10, S13, **S60–S62, S63, S71, S73, S136, S211**
- diabetes technology. *see* technology, diabetes.
- diabetic ketoacidosis, S17–S18, S249–S250
- diabetic kidney disease. *see* chronic kidney disease.
- Diabetic Retinopathy Study (DRS), S187
- diagnosis, S4, **S18–S26**
- confirmation of, S20
  - of diabetic kidney disease, S177
  - of diabetic neuropathy, S188–S189
  - diagnostic tests, S18–S20
  - type 1 diabetes, S20–S22
  - of type 1 vs type 2 in pediatric patients, S219
  - type 2 diabetes, S23–S25
- diagnostic tests, S18–S20
- A1C, S19–S20
  - age, S19–S20
  - confirmation of, S20
  - criteria for, S19
  - ethnicity, S20
  - fasting and 2-hr plasma glucose, S19
  - hemoglobinopathies, S20
  - prediabetes, S22–S23
  - race, S20
- diet
- for hypertension control, S148
  - for weight loss, S114–S115
- Dietary Reference Intakes, S236
- digital health technology, S105
- dipeptidyl peptidase 4 (DPP4) inhibitors, S28, S116, S133, S134, S135, S137, S159, S161, S166, S190, S200, S247
- disordered eating behavior, S73–S74
- do-it-yourself systems, S105
- domperidone, S190
- Dose Adjusted for Normal Eating (DAFNE), S5, S92
- DRCR Retina Network, S187
- driving, and diabetes, S255
- droxidopa, S190
- dulaglutide, S133, S137, S160, S165, S166, S167, S181
- duloxetine, S189
- dyslipidemia, S209, S210, S216–S217, S223
- e-cigarettes, S70, S217
- eating disorders, S73–S74
- eating patterns, S74–S75
- education, on device use, S98
- electrical stimulation, gastric, S190
- ELIXA trial, S160–S161
- EMPA-REG OUTCOME trial, S133, S161, S162, S163, S167, S180
- empagliflozin, S133, S137, S161, S164, S166, S167, S168, S180, S181
- EMPEROR-Reduced trial, S133, S162, S163, S164, S167
- employment, diabetes and, S255
- enalapril, S190
- end-of-life care, S204
- enteral/parenteral feedings, S248–S249
- erectile dysfunction, S56, S190
- ertugliflozin, S133, S137, S162, S164–S165, S247
- Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial (VERTIS CV), S6, S164–S165
- erythromycin, S190
- erythropoietin therapy, A1C and, S19
- estimated average glucose (eAG), S84
- ETDRS study, S187
- ethnicity
- effect on A1C, S20, S84–S85
  - in screening asymptomatic adults, S25–S26
  - in screening asymptomatic children/adolescents, S23
- evidence-grading system, S2
- evolocumab, S6, S153
- EXAMINE trial, S159, S167
- exenatide, S133, S137, S160, S166, S167, S221
- exercise. *see* physical activity.
- exocrine pancreas diseases, S17, **S30**
- EXSCEL trial, S133, S160–S161, S166
- eye exam, comprehensive, S186, S187, S218, S223
- ezetimibe, S6, S151, S152, S153, S155, S156
- family history, in screening children/adolescents, S23
- fasting plasma glucose (FPG) test, S18, S19, S20, S23, S26, S136
- fats, dietary, S66–S67
- FDA standards, for glucose meters, S99
- fenofibrate, S154
- fibrate + statin therapy, S154
- FLOW trial, S181
- fluvastatin, S152
- food insecurity, S11–S12
- foot care, S7, **S190–S192**
- footwear, S191
- FOURIER trial, S153
- fractures, **S55**

- gastroectomy, vertical sleeve, S119–S120
- gastric aspiration therapy, S119
- gastric bypass, Roux-en-Y gastric, S119–S120
- gastric electrical stimulation, S190
- gastrointestinal neuropathies, S189
- gastroparesis, S189, S190
- gemfibrozil, S154
- genetic testing, S4, S28, S29
- genitourinary disturbances, S189
- gestational diabetes mellitus (GDM), S4, S17, S22, S23, S25, **S30–S33**, S41, S42, S232, S235, S236, S237, **S239–S240**
- definition, S30–S31
- initial testing, S239
- insulin, S237
- management of, **S236–S237**
- medical nutrition therapy, S236–S237
- metformin, S237
- one-step strategy, S32
- physical activity, S237
- postpartum care, S239–S240
- recommendations, S30
- screening and diagnosis, S31–S33
- sulfonylureas, S237
- two-step strategy, S32–S33
- glargine, S126, S128, S138, S139, S140, S201
- glimepiride, S133, S137, S159, S161, S200
- glipizide, S133, S137, S200
- glomerular filtration rate, S176
- glucagon, S90, S91–S92
- glucagon-like peptide 1 receptor agonists (GLP-1 RA), S118, S130, S135, S136, S137, S139–S140, S168, S179, S180, S181, S186, S190
- glucocorticoid therapy, S26, S249
- glucose, for hypoglycemia, S90, S91
- glucose meters
- counterfeit strips, S99
- inaccuracy, S100
- interfering substances, S100
- oxygen, S100
- standards, S99
- temperature, S100
- glucose monitoring. *see* blood glucose monitoring.
- glucose-6-phosphate dehydrogenase deficiency, A1C and, S19, S20
- glucose-lowering therapy, S116, S127, S131
- in chronic kidney disease, S179–S182
- in hospitalized patients, **S246–S247**
- glulisine, S138, S201
- glyburide, S134, S137, S200, S236, S237
- glycemic control
- assessment of, **S83–S90**
- physical activity and, S69
- glycemic goals. *see also* glycemic targets., **S87–S90**
- glycemic targets, S5, **S83–S96**
- A1c and BGM correlation, S84
- A1C and cardiovascular disease outcomes, S87
- A1c differences in ethnic groups and children, S84–S85
- A1c limitations, S84
- continuous glucose monitoring, **S85–S87**
- in diabetic kidney disease, S179
- goals, **S87–S90**
- in hospitalized patients, **S245–S246**
- hypoglycemia, **S90–S92**
- individualization of, S89
- intercurrent illness, **S92**
- in older adults, S197–S198
- in pediatric type 1 diabetes, S213–S215
- in pediatric type 2 diabetes, S219–S220
- recommendations, S83
- setting and modifying A1C goals, S89–S90
- glycemic treatment, S6, **S125–S143**
- guanfacine, S190
- health literacy, S12–S13
- health numeracy, S4, S12–S13
- hearing impairment, S55
- heart failure, S144–S145, S166
- hemodialysis, A1C and, S20
- hemoglobinopathies, A1C on, S20
- hepatitis B vaccines, **S51**
- hepatitis C infection, S54–S55
- hepatitis, autoimmune, S53
- hip fractures, S55
- homelessness, S12
- hospital care, S7, S92, S106, **S244–S253**
- bedside glucose monitoring, **S246**
- care delivery standards, **S245–S246**
- glucose-lowering treatment in, **S246–S247**
- glycemic targets in, **S245–S246**
- hypoglycemia, **S247–S248**
- medical nutrition therapy in, **S248**
- medication reconciliation, S250
- perioperative care, S249
- preventing admissions and readmissions, **S250–S251**
- self-management in, **S248**
- standards for special situations, **S248–S250**
- structured discharge communication, S250
- transition to ambulatory setting, **S250**
- HOT trial, S146, S147
- housing insecurity, S12
- HPS2-THRIVE trial, S155
- human immunodeficiency virus (HIV), S20, S22, S26
- human papilloma virus (HPV) vaccine, S52
- human regular insulin, S138, S139, S249, S250
- hybrid closed-loop systems, S126
- Hydrogel, oral, S119
- hyperbaric oxygen therapy, S192
- hyperglycemia, S54
- Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study, S31
- hyperosmolar hyperglycemic state, S249–S250
- hypertension, **S145–S150**
- in pediatric type 1 diabetes, S209, S216
- in pediatric type 2 diabetes, S210, S223
- hypertriglyceridemia, S154
- hypoglycemia, S5, S54, **S90–S92**
- classification, S91
- in hospitalized patients, **S247–S248**
- in older adults, S196–S197
- prevention, S92
- recommendations, S901
- treatment, S91–S92
- hypoglycemia risk, S51
- hypoglycemia, postpartum, S120–S121
- hypogonadism, S55
- hypokalemia, S150
- icosapent ethyl, S154
- idiopathic type 1 diabetes, S21
- Illness, intercurrent, glycemic targets in, **S92**
- immune checkpoint inhibitors, S4
- immune-mediated diabetes, S21
- impaired fasting glucose (IFG), S18, S22, S23
- impaired glucose tolerance (IGT), S18, S19, S22, S23, S27, S32
- incretin-based therapies, S200
- Indian Diabetes Prevention Program (IDPP-1), S42
- infections, diabetic foot, S191–S192
- influenza, S5
- influenza vaccines, S5, **S48, S50–S54**
- inhaled insulin, S103, S126, S127, S138, S139
- injection techniques, S127
- in pediatric type 1 diabetes, S213–S215
- pens and syringes, S5, S102–103
- pumps, S103–S104
- insulin pump therapy, S99, S214
- insulin resistance, S17, S18, S22, S23, S24, S25, S26, S27, S68, S139, S224, S234, S235, S236, S237, S238, S239
- insulin secretagogues, S200
- insulin therapy, S28
- access and affordability, S254–S255
- in adults with type 1 diabetes, **S125–S130**
- in adults with type 2 diabetes, **S131–S141**, S140–S141
- basal, S99, S126, S139
- combination injectable, S139–S140
- concentrated insulins, S139
- in hospitalized patients, S246
- inhaled insulin, S103, S126, S127, S138, S139
- monitoring for intensive regimens, S99
- in older adults, S201
- prandial, S126–S127, S139
- insulin:carbohydrate ratio (ICR), S128–S129
- integrated CGM devices, S101–S102
- intensification, of therapy, S136
- intermittently scanned CGM devices, S101–S102
- International Association of the Diabetes and Pregnancy Study Groups (IADPSG), S31, S32
- International Diabetes Closed Loop (IDCL) trial, S126
- islet autotransplantation, S30, S55, S130–S131
- isradipine, S190
- juvenile-onset diabetes. *see* immune-mediated diabetes.
- KDIGO study, S177
- kidney disease. *see* chronic kidney disease
- Kumamoto study, S88
- language barriers, S12
- latent autoimmune diabetes in adults (LADA), S18
- LEADER trial, S160–S161, S165, S180
- lifestyle behavior changes
- for diabetes prevention, **S40–S42**
- for hypertension, S148
- for lipid management, S151
- in older adults, S198–S199

- in pediatric type 2 diabetes, S219  
in pregnancy, S236  
to reduce ASCVD risk factors, S151
- linagliptin, S133, S137, S159, S161, S167
- lipase inhibitors, S117
- lipid management, **S151–S155**
- lipid profiles, S151
- liraglutide, S42, S54, S116, S118, S133, S137, S140, S160, S165, S166, S167, S180, S181, S221, S222
- lispro, S138, S139, S201
- lixisenatide, S133, S137, S138, S140, S160, S166, S167
- long-acting insulin analog, in type 1 diabetes, S126, S128–S130, S135, S138, S139, S201, S202, S212, S214, S249
- Look AHEAD trial, S116
- loss of protective sensation, S188, S191
- lovastatin, S152
- macular edema, diabetic, S186
- maternal history, in screening children/adolescents, S23
- maturity-onset diabetes of the young (MODY), S18, **S28–S29**, S208, S219
- meal planning, S74–S75
- medical devices, for weight loss, S119
- medical evaluation, S5, **S46–S59**
- autoimmune diseases, **S53**
  - cancer, **S53**
  - cognitive impairment/dementia, **S53–S54**
  - comprehensive, **S48–S51**
  - fractures, **S55**
  - hepatitis C infection, **S54–S55**
  - immunizations, **S48, S50–S54**
  - low testosterone in men, **S55–S56**
  - nonalcoholic fatty liver disease, **S54, S55**, S56
  - obstructive sleep apnea, **S56**
  - pancreatitis, **S55**
  - periodontal disease, **S56**
  - recommendations, S48
- medical nutrition therapy, **S62–S67**
- alcohol, **S67**
  - carbohydrates, **S65–S66**
  - eating patterns and meal planning, **S64–S65**
  - fats, **S66–S67**
  - goals of, **S64**
  - in hospitalized patients, **S248**
  - micronutrients and supplements, **S67**
  - protein, **S66**
  - recommendations, S63
  - sodium, **S67**
  - weight management, **S64**
- medications
- considerations in pregnancy, S239–S240
  - cost considerations, S4, S10
  - in diabetes screening, S26
  - glucose-lowering, impact on weight, S116
  - for weight loss, S116–S119
- Mediterranean diet, S151
- meglitinides, S51, S137
- mental health referrals, S72, S73
- mental illness, serious, S74
- metabolic surgery, S119–S121, S221–S222
- metformin, S5, S6, S7, S28, S30, S42, S67, S88, S89, S116, S130, S131, S132, S133, S135, S137, S139, S140, S158, S159, S160, S162, S165, S166, S168, S179, S180, S196, **S200**, S201, S210, S220, S221, S223, S236, **S237**, S238, S239, S249
- metoclopramide, S190
- metoprolol, S190
- micronutrients, S67
- microvascular complications, S69–S70
- A1C and, S87–S88
  - in pediatric type 1 diabetes, S217–S218
- midodrine, S190
- miglitol, S137
- migrant farmworkers, S12
- mineralocorticoid receptor antagonist therapy, S150–S151, S181
- monogenic diabetes syndromes, S17, **S28–S30**
- multiple daily injections (MDI), S99
- myasthenia gravis, S53
- naltrexone/bupropion ER, S116, S117
- nateglinide, S42, S137
- National Diabetes Data Group, S33
- National Diabetes Prevention Program, S41
- National Health and Nutrition Examination Survey (NHANES), S9, S19, S55, S219
- neonatal diabetes, S17, **S28**
- nephrologist, referral to, S182
- nephropathy
- in pediatric type 1 diabetes, S209, S217
  - in pediatric type 2 diabetes, S210, S222
- neurocognitive function, S196
- neuropathy, S7, S70, **S188–S190**
- in pediatric type 1 diabetes, S209, S218
  - in pediatric type 2 diabetes, S210, S223
- new-onset diabetes after transplantation (NODAT), S27
- niacin + statin therapy, S154–S155
- nonalcoholic fatty liver disease (NAFLD), S5, S54, S55, S56
- in pediatric type 2 diabetes, S210, S223
- nonalcoholic steatohepatitis (NASH), S5, S54
- noninsulin treatments
- in type 1 diabetes, S127, S130
- noninsulin-dependent diabetes. *see* type 2 diabetes.
- nonnutritive sweeteners, S67
- NPH insulin, S126, S127, S128–S130, S133, S135, S138, S139, S140, S201, S247, S249
- nucleoside reverse transcriptase inhibitors
- A1C and, S20
- nursing homes, S203–S204
- nutrition therapy
- and dementia, **S54**
  - for diabetes prevention, **S40–S41**
  - with diabetic kidney disease, S179
  - in pediatric type 1 diabetes, S211
- obesity, S5, **S113–S124**
- assessment, S113–S114
  - diet, physical activity, and behavioral therapy, **S114–S119**
  - medical devices for weight loss, **S119**
  - metabolic surgery, **S119–S121**
  - pharmacotherapy, **S116–S119**
  - screening asymptomatic children/adolescents, S23
- obstructive sleep apnea, S56
- in pediatric type 2 diabetes, S210
- ODYSSEY OUTCOMES trial, S153
- older adults, S7, **S195–S207**
- end-of-life care, S204
  - hypoglycemia, S196–S197
- lifestyle management, S198–S199
- neurocognitive function, S196
- pharmacologic therapy, S199–S203
- in skilled nursing facilities and nursing homes, S203–S204
  - treatment goals, S197–S198
  - with type 1 diabetes, S203
- one-step strategy, for GDM, S32
- opioid antagonist/antidepressant combination, S117
- ophthalmologist, referral to, S186, S218, S224, S234
- oral agents, BGM for patients using, S99
- oral glucose tolerance test (OGTT), S18, S19, S23, S26, S27, S28, S29, S31, S32, S33, S236
- organ transplantation, posttransplantation diabetes mellitus, S17, **S27–S28**
- orlistat, S116, S117
- orthostatic hypotension, S190
- overweight, screening asymptomatic children/adolescents, S23
- oxygen, glucose monitors and, S100
- P2Y12 receptor antagonists, S155, S157
- palliative care, S204
- pancreas transplantation, S130–S131
- pancreatectomy, S30
- pancreatic diabetes, S17, **S30**
- pancreatitis, **S55**
- pancreoprivic diabetes, S30
- patient-centered care goals, **S43**
- patient-centered collaborative care, **S46–S48**
- pens, insulin, S102–S103
- periodontal disease, S26, S56
- perioperative care, S249
- peripheral arterial disease, S191
- peripheral neuropathy, S70
- peripheral neuropathy, diabetic, S188
- pernicious anemia, S53
- pharmacologic approaches. *see also* specific medications, medication classes., S6, **S125–S143**
- for adults with type 1 diabetes, **S125–S130**
  - for adults with type 2 diabetes, **S131–S141**
  - for hypertension, S149–S151
  - in older adults, S199–S203
  - for pediatric type 2 diabetes, S220–S221
  - in prediabetes, **S42**
  - for weight loss, **S116–S119**
- phentermine, S116, S117
- phentermine/topiramate ER, S116, S117
- phosphodiesterase type 5 inhibitors, S190
- photocoagulation surgery, S187
- physical activity, **S41, S67–S70**
- for diabetes prevention, **S41**, S114–S115
  - for diabetes treatment, S114–S115
  - frequency and type, **S67–S68**
  - glycemic control and, **S68**
  - with microvascular complications, **S68–S70**
  - in pediatric type 1 diabetes, S211
  - pre-exercise evaluation, **S68**
- pioglitazone, S55, S133, S137, S154
- PIONEER-6 trial, S160–S161, S165
- pitavastatin, S152
- Plenity, S119
- pneumococcal pneumonia vaccines, **S51**, S52
- polycystic ovarian syndrome, S210
- population health, S4, **S8–S16**

- care delivery systems, S9–S11  
 recommendations, S8  
 social context, S11–S13
- postbariatric hypoglycemia, S120–S121
- postpancreatitis diabetes mellitus (PPDM), S30
- postpartum care, in diabetic women, S239–S240
- postpartum state, A1C in, S20
- posttransplantation diabetes mellitus, S17, **S27–S28**
- pramlintide, S127, S130, S137, S190
- prandial insulin, S126–S127, S139
- pravastatin, S152
- pre-eclampsia, in pregnant women with diabetes, S239
- prediabetes  
 criteria defining, S23  
 diagnosis, S23  
 prevention of vascular disease and mortality, **S42–S43**  
 screening, S4, S22–S23
- pregabalin, S116, S189
- pregnancy, S7, **S232–S243**  
 A1C and, S20, S235  
 continuous glucose monitoring in, S235–S236  
 diabetes in, S232  
 drug considerations in, **S238–S239**  
 eye exams during, S186  
 gestational diabetes mellitus (GDM), S4, S17, S22, S23, S25, **S30–S33**, S41, S42, S232, S235, S236, S237, **S239–S240**  
 glucose monitoring in, S235  
 glycemic targets in, **S234–S236**  
 insulin in, S237  
 metformin in, S237  
 pharmacologic therapy, S237  
 physical activity in, S237  
 postpartum care, **S239–S240**  
 pre-existing type 1 and 2 diabetes in, 240, **S237–S238**  
 preconception counseling, **S233–S234**  
 preeclampsia and aspirin, **S238**  
 real-time CGM device use in, S102  
 retinopathy during, S187  
 sulfonyleureas, S237
- prevention, type 2 diabetes, S4–S5, **S39–S45**  
 lifestyle behavior change, **S40–S42**  
 patient-centered care goals, **S43**  
 pharmacologic interventions, **S42**  
 recommendations, S39, S40, S42, S43  
 of vascular disease and mortality, **S42–S43**
- proliferative diabetic retinopathy, S186
- proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, S151, S153, S155
- protease inhibitors, A1C and, S20
- protein intake, S66
- psychosocial issues, **S70–S75**  
 anxiety disorders, S71  
 cognitive capacity/impairment, S74–S75  
 depression, S71–S72  
 diabetes distress, S70–S71  
 disordered eating behavior, S73–S74  
 in pediatric type 1 diabetes, S212–S213  
 in pediatric type 2 diabetes, S224  
 referral to mental health specialist, S72, S73  
 serious mental illness, S74  
 pumps, insulin, S99, S103–S104
- quality improvement, S10–S11
- race  
 effect on A1C, S20  
 in screening asymptomatic children/adolescents, S23
- rapid-acting insulin analog, S103, S105, S125, S127–S130, S138, S139, S201, S212, S235, S248, S249, S250
- real-time CGM devices, S101, S213, S214
- REDUCE-IT trial, S154
- referrals, S5  
 to behavioral health provider, S196  
 for comprehensive eye exam, S186, S218, S224, S234  
 for DSME, S196  
 to gastroenterologist, S223  
 to nephrologist, S182, S223  
 to neurologist, S188  
 to pediatric sleep specialist, S223  
 to registered dietitian, S233, S235, S250
- reimbursement, for DSMES, S62
- repaglinide, S137
- retinopathy, diabetic, S6, S7, S25, S51, S68, S69, S70, S87, S104, S147, S177, S181 **S185–S188**, S190, S209, S210, S215, S218, S223, S233, S234, S238  
 in pediatric type 1 diabetes, S209, S218  
 in pediatric type 2 diabetes, S210, S223
- REWIND trial, S160–S161, S165
- risk calculator, for ASCVD, S145
- risk management  
 cardiovascular disease, S6, **S144–S174**  
 chronic kidney disease, S6–S7, **S175–S184**
- risk, determination of, S24
- rivaroxaban, S155, S157
- rosiglitazone, S133, S137
- rotuvastatin, S152
- Roux-en-Y gastric bypass, S119–S120
- SAVOR-TIMI trial, S159, S167
- saxagliptin, S133, S137, S159, S167, S247
- schizophrenia, S74
- schools  
 device use in, S98  
 diabetes care in, S255  
 pediatric type 1 diabetes and, S212
- screening  
 for cardiovascular disease, **S157–S158**  
 in children/adolescents, S26  
 community, S26  
 in dental practices, S26  
 for gestational diabetes mellitus, **S30–S33**  
 HIV, S26  
 medications, S26  
 for neuropathy, S188  
 for prediabetes and type 2 diabetes, S22–S26  
 testing interval, S26  
 for type 1 diabetes, S20–S22
- seasonal farmworkers, S12
- self-monitoring of blood glucose (SMBG). *see* blood glucose monitoring (BGM)
- semaglutide, S5–S6, S54, S55, S116, S118, S133, S137, S160, S161, S165, S167, S180, S181, S200
- sensor-augmented pumps, S104–S105
- sensory impairment, S55
- setmelanotide, S116
- sexual dysfunction, S189
- sickle cell disease, A1C and, S20
- simvastatin, S152
- sitagliptin, S133, S137, S159, S167
- skilled nursing facilities, S203–S204
- smart pens. *see* connected insulin pens
- smoking cessation, **S70**, S218
- social capital, S13  
 social context, S11–S13  
 social determinants of health (SDOH), S9, S11–S13  
 sodium intake, S67  
 sodium–glucose cotransporter 2 (SGLT2) inhibitors, S6, S7, S88, S89, S130, S133, S135, S137, S140, S145, S161, S162, S163, S165, S166, S167, S168, S178, S179, S180, S181, S197, S200, S247, S249
- SOLOIST-WHF trial, S167
- sotagliflozin, S167
- SPRINT trial, S146, S147
- staging  
 of diabetic kidney disease, S177–S178  
 of type 1 diabetes, S18
- statin treatment, S151–S155
- statins, S54
- sulfonyleureas, S12, S28, S29, S85, S133, S137, S140, S200, S237
- supplements, S67
- surveillance, of chronic kidney disease, S178–S179
- SUSTAIN-6 trial, A160–S161, S180
- sweeteners, nonnutritive, S67
- sympathomimetic amine anorectic/antiepileptic combination, S117
- sympathomimetic amine anorectics, S117
- syringes, insulin, S102–S103
- tapentadol, S189–S190
- technology, diabetes, S5, **S97–S112**  
 blood glucose monitoring, **S98–S100**  
 continuous glucose monitoring devices, **S100–S102**  
 general device principles, **S97–S98**  
 insulin delivery, **S102–S106**
- TECOS trial, S159, S167
- TEDDY study, S22
- telemedicine, S10
- temperature, of glucose monitor, S100
- testing interval, S26
- testosterone, low, in men, **S55–S56**
- tetanus, diphtheria, pertussis (TDAP) vaccine, S52
- thiazide-like diuretics, S26, S150, S182
- thiazolidinediones, S28, S42, S55, S116, S133, S137, S166, **S200**
- thyroid disease, autoimmune, S53  
 in pediatric type 1 diabetes, S209, S215
- tobacco, S70
- training, on device use, S98
- transfusion, A1C and, S20
- transition  
 from hospital to ambulatory setting, S250  
 from pediatric to adult care, S224
- transplantation  
 islet, S91, S130–S131  
 organ, post-transplant diabetes mellitus after, S17, S27, S28  
 pancreas, S130–S131  
 simultaneous renal, S130, S131, S165, S167, S177, S180

- tricyclic antidepressants, S190  
 TWILIGHT trial, S157  
 two-hour plasma glucose (2-h PG) test, S18, S19  
 two-step strategy, for GDM, S32–S33  
 type 1 diabetes, S4  
   A1C and cardiovascular disease outcomes in, S88  
   beta-cell replacement therapy, S130–S131  
   in children/adolescents, **S211–S218**  
   classification, **S17–S18**  
   diagnosis, S4, **S20–S22**  
   examples of subcutaneous insulin regimens, S128–S130  
   idiopathic, 21  
   immune-mediated, 21  
   insulin therapy in hospitalized patients, S247  
   noninsulin treatments, S127, S130  
   in older adults, S203  
   pharmacologic treatment in adults, **S125–S130**  
   pregnancy in women with preexisting, S239  
   retinopathy in, S186  
   screening, S4, S21–S22  
   staging, S18  
   surgical treatment, **S130–S131**
- type 2 diabetes, S4  
   A1C and cardiovascular disease outcomes in, S88–S89  
   in children/adolescents, **S218–S224**  
   classification, S4, **S17–S18**  
   combination therapy, S132, S135  
   drug-specific and patient factors to consider, S133  
   initial therapy, S132  
   insulin pump use in, S105  
   obesity and weight management, S5, **S113–S124**  
   pharmacologic treatment in adults, **S131–S141**  
   pregnancy in women with preexisting, S238  
   prevention or delay, S4–S5, **S39–S45**  
   retinopathy in, S186–S187  
   risk test for, S24  
   screening in asymptomatic adults, S4, S25–S26  
   screening in children/adolescents, S4, S26
- type 3c diabetes, S30
- UK Prospective Diabetes Study (UKPDS), S87, S88, S89, S90, S158
- ulcers, foot, S190, S191, S192  
 ultra-rapid-acting insulin analogs, S127–S130, S249
- vagus nerve stimulator, S119  
 vascular disease, prevention of, in prediabetes, **S42–S43**  
 venlafaxine, S190  
 VERIFY trial, S135  
 vertical sleeve gastrectomy, S119–S120  
 Veterans Affairs Diabetes Trial (VADT), S87–S88, S179  
 vildagliptin, S135  
 vitamin D supplementation, S5  
 VOYAGER-PAD trial, S157
- weight loss surgery. *see* metabolic surgery.  
 weight loss/management  
   in diabetes prevention, S40, S41, S42, S43, **S113–S124**  
   in type 2 diabetes, S5, S64, **S113–S124**  
 well-being, S5, S10, **S60–S82**  
 whites, non-Hispanic, A1C differences in, S84–S84  
 zoster vaccine, S53